Anderson-fabry disease: A multiorgan disease

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5974-5996

  Tuttolomondo, Antonino ^a   Pecoraro, Rosaria ^a   Simonetta, Irene ^a   Miceli, Salvatore ^a   Pinto, Antonio ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anderson Fabry disease; Disease; Multiorgan

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGRAPHY; ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; EXERCISE TEST; FABRY DISEASE; HEALTH SURVEY; HEART LEFT VENTRICLE HYPERTROPHY; HETEROZYGOTE; HUMAN; KIDNEY CELL; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SKIN BIOPSY; TISSUE DOPPLER IMAGING; VASCULAR DISEASE;

AGE FACTORS; CENTRAL NERVOUS SYSTEM; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; KIDNEY; MALE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; SKIN;

EID: 84884244536     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990352     Document Type: Article

References (60)

1. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, Editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis 2006. Chapter 2.
2. Nagueh SF. Fabry disease. Heart 2003; 89: 819-20.
3. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 1427-35.
4. Mehta A, Clarke JT, Giugliani R, et al. FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet 2009; 46(8): 548-52.
5. Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Virchows Arch Pathol Anat Histopathol 1990, 417: 449-55. 29.
6. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333: 288-93.
7. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003, 64: 801-7.
8. Dominique P Germain. Fabry disease. Orphanet J Rare Dis 2010, 5: 30.
9. Maier EM, Osterrieder S, Whybra C, et al. Disease manifestations and × inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 2006, 95: 30-38;
10. Migeon BR: X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol 2008, 19: 2052-9.
11. Germain DP, Avan P, Chassaing A, Bonfils P (2003). Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twentytwo hemizygous male patients. BMC Med Genet 2002; 3: 10.
12. Macdermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38(11): 769-75.
13. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 2006; 43(4): 347-52.
14. Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet 2003; 40(4): e38.
15. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005; 84(5): 261-8.
16. Kobayashi Macdermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38(11): 750-60.
17. Bouwman MG, Rombach SM, Schenk E, et al. Prevalence of symptoms in female Fabry disease patients: a case-control survey. J Inherit Metab Dis 2012; 35(5): 891-8.
18. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Fabry Registry Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93(2): 112-28.
19. Valbuena C, Oliveira JP, Carneiro F, et al. Kidney histologic alterations in α-alactosidase-deficient mice. Virchows Arch 2011; 458(4): 477-86.
20. Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001; 24 Suppl 2: 66-70.
21. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62(6): 1933-46.
22. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18(5): 1547-57.
23. Aakre KM, Tondel C, Brun A, et al. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clin Nephrol 2009; 71: 118-24.
24. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30.
25. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23: 117-34.
26. Hutchings A, Raine R, Sanderson C, et al. A comparison of formal consensus methods used for developing clinical guidelines. J Health Serv Res Policy 2006; 11: 218-24.
27. Fogo AB, Bostad L, Svarstad E, et al. all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25(7): 2168-77.
28. Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy-a short review. NDT Plus 2008; 1: 11-19.
29. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257: 258-63.
30. Schiffmann R. Fabry disease, Pharmacol Ther 2009; 122: 65-77.
31. Walter E. Mix M, Lohr K, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study, Lancet 2005; 366: 1794-6.
32. Sessa A, Meroni M, Battini G, et al. Renal pathologicalchanges in Fabry disease, J Inherit Metab Dis 2001; 24(Suppl. 2): 66-70.
33. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease, Z Kardiol 2002; 91: 786-95.
34. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-46.
35. Barbey F, Brakch N, Linhart A, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition, Arterioscler. Thromb Vasc Biol 2006; 26: 839-44.
36. Sachdev B, Tome M, Ward D, Lee P, Metha AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842-6. 3.
37. Igawa O, Miake J, Hisatome I. Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol 2005; 28: 1142-3.
38. Shah JS. Hughes cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol 2005; 28: 1142-3.
39. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986; 7: 1157-61
40. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-8.
41. Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011; 4(6): 592-601
42. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26(12): 1221-7.
43. Petritsch B, Köstler H, Machann W, et al. Non-invasive Determination of Myocardial Lipid Content in Fabry Disease by 1H-MR Spectroscopy. Rofo 2012; 184(11): 1020-5.
44. Rombach SM, van den Bogaard B, de Groot E, et al. Vascular aspects of fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012; 60(4): 998-1005.
45. Marcì M, Duro G, Tuttolomondo B, Pinto A, Cirrincione V, Sanfilippo N. Delayed diagnosis of Fabry disease presenting as myocardial ischaemia. Hellenic J Cardiol 2012; 53(1): 77-9.
46. Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008; 79(11): 1249-54.
47. Marino S, Borsini W, Buchner S, et al. Diffuse structural and metabolic brain changes in Fabry disease J Neurol 2006; 253(4): 434-40.
48. Tagliavini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A. Anderson-Fabry's disease: neuropathological and neurochemical investigation. Acta Neuropathol 1982; 56(2): 93-8.
49. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Neuron protection as a therapeutic target in acute ischemic stroke. Curr Top Med Chem 2009; 9(14): 1317-34.
50. Tuttolomondo A, Pinto A, Corrao S, et al. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 2009; 203(2): 503-8.
51. Tuttolomondo A, Pinto A, Salemi G, et al. Diabetic and nondiabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis 2008; 18(2): 152-7.
52. Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G. Risk factors profile and clinical outcome of ischemic stroke patients admitted in a Department of Internal Medicine and classified by TOAST classification. Int Angiol 2006; 25(3): 261-7.
53. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype. Atherosclerosis 2010; 211(1): 187-94.
54. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Immuneinflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke. Atherosclerosis 2010; 213(1): 311-8.
55. Navarro C, Teijeira S, Dominguez C, et al. Cutaneous lesion which allowed the definition of Fabry disease. In a recent study authors investigated (Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients). Acta Neuropathol 2006; 111(2): 178-85.
56. Orteu CH, Jansen T, Lidove O, et al. FOS Investigators-Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007; 157(2): 331-7.
57. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65(4): 299-307.
58. Altarescu G, Chicco G, Whybra C, et al. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis. 2008; 31(1): 117-23.
59. Safyan R, Whybra C, Beck M, Elstein D, Altarescu G. An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw 2006; 17(4): 271-5.
60. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30(2): 184-92.